Archived NCCN Tumor Boards: The Role of Molecular Profiling in the Management of Uterine Cancer

Determining treatment regimens for patients with uterine cancer can be challenging. With the availability of increasingly advanced imaging, surgical, and radiation therapy techniques as well as novel systemic therapy options, evidence-based guidance is needed to inform and optimize treatment decisions. The NCCN Guidelines® for Uterine Neoplasms provide primary and adjuvant treatment recommendations according to tumor histology, resectability status, the extent of disease, pathology, molecular analysis, and surgical staging results. The recommendations in these Guidelines are stratified by both preference and strength of evidence and consensus, which help clinicians make informed, evidence-based treatment decisions.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Integrate recent advances in molecular analysis into a clinical framework.
  • Discuss how molecular characterization affects prognosis and helps guide decision making in both early-stage and late-stage uterine cancer. 
  • Discuss how molecular profiling predictive factors can influence adjuvant therapy for patients with uterine cancer.

You may also be interested in

Recorded Presentation from the NCCN Pharmacy Updates: Updates in Ovarian Cancer - Putting Together the PARP Puzzle and Understanding a New Therapeutic Target
The flurry of changes to the PARPi indications can cause considerable confusion in clinical practice. It may be difficult for health care professionals to keep track of the emerging data and understand how to apply it to patient care. It is important that health care professionals, including pharmacists, are able to educate their patients on the risks vs. benefits of these agents to help empower them to make informed decisions regarding their treatment.
Archived Monthly Oncology Tumor Boards: Management of Advanced Ovarian Cancer
Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Eisai Inc.
  • Genentech, a member of the Roche Group
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Novartis
  • Sanofi

This activity is supported by independent educational grants from:

  • Daiichi Sankyo
  • Merck & Co., Inc., Rahway, NJ, USA

This is activity is supported by independent medical education grants from:

  • AbbVie
  • GSK
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
09/10/2024
Course expires: 
09/10/2025
Cost:
$0.00
Part of: 
Archived NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care

Natalia Buza, MD
Yale Cancer Center/Smilow Cancer Hospital

Shari Damast, MD
Yale Cancer Center/Smilow Cancer Hospital

Elena Ratner, MD, MBA
Yale Cancer Center/Smilow Cancer Hospital

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no financial relationships with ineligible companies to disclose.

Shari Damast, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Natalia Buza, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Daiichi-Sankyo Co.: Scientific Advisor

Elena Ratner, MD, MBA
Zai Lab Ltd: Honoraia

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-102-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until September 10, 2025. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00060461; Approval #: 240002530

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing